X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
The proceeds will be used for the finalization of the late-stage development of the lead candidate ITM-11 (n.c.a. 177Lu-edotreotide), a targeted radiopharmaceutical currently being evaluated in phase III for the treatment of gastroenteropancreatic neuroendocrine tumors.
Lead Product(s): n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Indigenous Critical Infrastructure Fund Canada
Deal Size: $36.3 million Upfront Cash: Undisclosed
Deal Type: Financing March 22, 2022
Details:
ITM-11, a targeted radionuclide therapy consisting of high-quality radioisotope, no-carrier-added lutetium-177 combined with somatostatin analog edotreotide is best standard of care for patients with neuroendocrine tumors.
Lead Product(s): n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
The equity investment follows the licensing agreement between companies which provides GP with rights to develop, manufacture and commercialize ITM’s precision oncology radiopharmaceutical candidates, ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate).
Lead Product(s): Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: $588.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 16, 2022
Details:
ITM-11 (177Lu-edotreotide), a synthetic form of the peptide hormone somatostatin that targets neuroendocrine tumor-specific receptors demonstrated promising results in its trial for the treatment of hard-to-treat tumors.
Lead Product(s): n.c.a. Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2022
Details:
Under the terms of the agreement, ITM grants GP an exclusive license for the ITM-11 (n.c.a. 177Lu-edotreotide) and ITM-41 (n.c.a. 177Lu-zoledronate), in the licensed territory and will support the supply of the pharmaceuticals needed for clinical and commercial activities.
Lead Product(s): Lutetium-177-edotreotide,L-Arginine,Lysine
Therapeutic Area: Oncology Product Name: ITM-11
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Grand Pharmaceutical Group Limited
Deal Size: $588.4 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 27, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
